WO2022054904A1

WO2022054904A1 - Food composition, pharmaceutical composition, quasi drug composition, cosmetic composition and sundry article for preventing or treating covid-19

Info

Publication number: WO2022054904A1
Application number: PCT/JP2021/033292
Authority: WO
Inventors: 明秀梁; 敬宮川; 武志森田; 智子國吉; 金緯楊
Original assignee: 公立大学法人横浜市立大学; 株式会社常磐植物化学研究所
Priority date: 2020-09-11
Filing date: 2021-09-10
Publication date: 2022-03-17
Also published as: JP2022047447A

Abstract

The purpose of the present invention is to provide a food composition, a pharmaceutical composition, a quasi drug composition, a cosmetic composition and a sundry article, each being for preventing or treating COVID-19. A food composition, a pharmaceutical composition, a quasi drug composition, a cosmetic composition and a sundry article, each being for preventing or treating COVID-19 and comprising at least one member selected from among a cat's claw extract, a ginger extract, pteropodine and a pharmaceutically acceptable salt thereof, isopteropodine and a pharmaceutically acceptable salt thereof, 6-gingerol and a pharmaceutically acceptable ether thereof and 6-shogaol and a pharmaceutically acceptable ether thereof.

Description

Food compositions, pharmaceutical compositions, quasi-drug compositions, cosmetic compositions, and miscellaneous goods for the prevention or treatment of new coronavirus infections.

The present invention relates to food compositions, pharmaceutical compositions, quasi-drug compositions, cosmetic compositions, and miscellaneous goods for the prevention or treatment of new coronavirus infections.

The new coronavirus infection (COVID-19) was confirmed in Wuhan City, Hubei Province, China in December 2019, and the infection has spread all over the world. The causative new coronavirus (SARS-CoV-2) is a type of coronavirus and is a plus-strand RNA virus belonging to the coronavirus subfamily of the coronaviridae family. In addition to the common causes of colds, coronaviruses include the Severe Respiratory Syndrome (SARS) virus that prevailed mainly in Asia in 2003 and the Middle East Respiratory Syndrome (MERS) virus that has spread in the Middle East since 2012. .. The main symptoms of the new coronavirus infection are fever, general malaise, and respiratory symptoms. About 80% of them are cured with mild symptoms, but about 20% have worsening pneumonia and about 5% have artificial respiration management. It is said that this is a serious case that requires, and there have been reports of cases in which the condition deteriorates sharply. As a factor of aggravation, it is considered that an excessive immune reaction occurs due to a cytokine storm, which is an excessive release of cytokines from immune cells, and an organ such as a lung is damaged.

In addition, as of the filing date of this case, there is no specific therapeutic drug for the new coronavirus infection, and the existing drug is only diverted. It has been confirmed that the anti-Ebola virus drug remdesivir has the effect of shortening the treatment period for patients infected with the severe new coronavirus, and has received special approval in Japan. However, as a general rule, the subjects of medication are severely ill patients, and there are concerns about safety, such as the high frequency of renal dysfunction and hepatic dysfunction. Another problem is that the supply of remdesivir is limited. In addition, it has been reported that dexamethasone, a steroid drug, also reduced the number of deaths in severe cases, and it was approved as the second treatment drug for new coronavirus infection in Japan. It is recommended for use in, and no cure has been established for mildly ill patients. Other therapeutic agents are off-label use, and their efficacy and safety are unclear during verification. In addition, although there are vaccines for which clinical trials have been started for vaccination that is generally effective as a means of preventing virus infection, it has not been put into practical use. Under these circumstances, it is an urgent task to develop preventive and therapeutic agents that are effective against the new coronavirus, are highly safe, and can be stably supplied.

On the other hand, there is a report using the molecular docking method for the interaction between naturally occurring components and the new coronavirus (SARS-CoV-2) protein, and epigallocatechin gallate, anthocyanidins, curcumin, etc. may have antiviral effects. It is shown as being (Non-Patent Documents 1 and 2).

However, these are the results of computer simulations, and their effects have not been demonstrated at the cellular or animal level. As mentioned above, there are still concerns about the safety of the therapeutic agents currently used, and the supply is limited. Therefore, prevention or prevention using natural products with high safety and easy availability of raw materials can solve these problems. It is desired to provide therapeutic food compositions, pharmaceutical compositions, quasi-drug compositions, cosmetic compositions, miscellaneous goods and the like.

It is an object of the present invention to solve the above-mentioned conventional problems and to achieve the following objects. That is, the present invention is a food composition, a pharmaceutical composition, a quasi-drug composition, a cosmetic product for the prevention or treatment of a new type of coronavirus infection containing a natural product which is highly safe and whose raw material is easily available. The purpose is to provide compositions and miscellaneous goods.

In order to solve the above problems, the inventor of the present invention relates to a prophylactic or therapeutic agent for a new type of coronavirus infection, which is a highly safe natural product and can be widely used in foods, pharmaceuticals, quasi-drugs, cosmetics, and miscellaneous goods. As a result of repeated diligent studies, the present invention was reached.

That is, the present invention relates to cat's claw extract, ginger extract, Pteropodine and its quasi-drugs, Isopteropodine and its quasi-drugs, 6-Gingerol and its quasi-drugs ether. In addition, food compositions, pharmaceutical compositions, quasi-drugs having prophylactic or therapeutic effects against the new coronavirus, preferably containing at least one of 6-Gingerol and its pharmaceutically acceptable ethers, preferably as an active ingredient. A composition, a cosmetic composition or a quasi-drug. So far, the effects of cat's claw extract, ginger extract, Pteropodine, Isopteropodine, 6-Gingerol, and 6-Shogalol on the new coronavirus have not been known at all, and it is a new finding by the present inventors.

More specifically, the present invention is as follows. That is, the prophylactic or therapeutic agent for the new coronavirus infection according to one aspect of the present invention contains a cat's claw (Uncaria tomentosa) extract, and is preferably blended with this as an active ingredient. Here, "agent" in a preventive agent or a therapeutic agent is a term used as an auxiliary term, and "agent" is used as a meaning of a substance having a pharmacological function, but this does not necessarily mean a pharmaceutical composition (drug). This preventive agent and therapeutic agent can be used as an active ingredient in food compositions, pharmaceutical compositions, quasi-drug compositions, cosmetic compositions, or miscellaneous goods.

Further, the prophylactic or therapeutic agent for a new type of coronavirus infection according to another aspect of the present invention contains a ginger (Zingiber office) extract, and is preferably blended with this as an active ingredient. ..

Further, the prophylactic or therapeutic agent for a new type coronavirus infection according to another aspect of the present invention contains at least one of Pteropodine and a pharmaceutically acceptable salt thereof, and is preferable. Is compounded as an active ingredient.

In addition, the prophylactic or therapeutic agent for a new type of coronavirus infection according to another aspect of the present invention contains at least one of Isopteropodyne and a pharmaceutically acceptable salt, which is preferably used. It is compounded as an active ingredient.

Further, the prophylactic or therapeutic agent for the new coronavirus infection according to another aspect of the present invention contains at least one of 6-Gingerol and a pharmaceutically acceptable ether, and is preferable. This is blended as an active ingredient.

In addition, the pharmaceutical composition for preventing or treating a new type of coronavirus infection according to another aspect of the present invention contains at least one of 6-shogaol and a pharmaceutically acceptable ether. This is preferably blended as an active ingredient.

As described above, according to the present invention, food compositions, pharmaceutical compositions, quasi-drug compositions, cosmetics for the prevention or treatment of new coronavirus infections containing natural products that are highly safe and easily available as raw materials are used. Compositions and miscellaneous goods can be provided. The present invention is a naturally derived extract or compound, and since it is excellent in safety, it is suitable for use in foods, pharmaceuticals, quasi-drugs, cosmetics, and miscellaneous goods.

A brief description of the figures in the examples is as follows.
It is a figure which shows the infection suppression effect of the new type coronavirus of Production Examples 1 to 4. It is a figure which shows the result of the immunostaining using the antibody against SARS-CoV-2 Nprotein. It is a graph regarding the confirmation of the infection suppression effect on SARS-CoV-2. It is a figure which shows the result about the inhibitory effect on the cleavage of a polyprotein by a protease.

Hereinafter, embodiments of the present invention will be described in detail. The present invention can be implemented in many different embodiments and is not limited to the specific examples of the embodiments and examples shown below.

The prophylactic or therapeutic agents for the novel coronavirus infection of the present invention include cat's claw extract, ginger extract, Pteropodine and its pharmaceutically acceptable salt, Isopteropodine and its pharmaceutically acceptable salt, 6-Gingerol. And its pharmaceutically acceptable ether, and at least one of 6-shogaol and its pharmaceutically acceptable ether, preferably containing at least one of these as an active ingredient. It also contains other ingredients as needed.

The cat's claw extract and ginger extract can be easily obtained by a method generally used for extracting plants. In addition, each plant extract includes an extract of an extraction raw material, a dried product obtained by drying a diluted solution of the extract, or a crude product or a purified product thereof. The site where the extraction raw material is used is not limited as long as the above effects can be obtained, but it is preferable to use bark for the cat's claw extract and rhizome for the ginger extract.

Further, the extraction method of the above plant extract is not particularly limited, and can be carried out according to a method well known to those skilled in the art. As the extraction solvent, water, an alcohol solvent, and an organic solvent such as acetone, esters, polyhydric alcohols, and ethers can be used. These solvents may be used alone or in combination. Among these, it is preferable to use ethanol, and it is more preferable to use hydrous ethanol having an ethanol content of 10% to 95% (v / v). The amount of the extraction solvent, the extraction temperature, the extraction time and the extraction method are not limited as long as the present composition exhibiting the above effects can be obtained. The amount of the extraction solvent is preferably 1 to 100 parts by weight with respect to the dry weight of the raw material. The extraction temperature is preferably 4 to 90 ° C. The extraction time is preferably 30 minutes to 1 week. The extraction method can be any method such as stirring extraction, immersion extraction, countercurrent extraction, ultrasonic extraction, and supercritical extraction.

Further, the above-mentioned extract is a filtrate itself obtained by filtering the obtained extract, a concentrated solution obtained by concentrating the filtrate, a dried product obtained by drying the concentrated solution, and a crude or purified product thereof. May be good. The concentration method and the drying method can be performed by any method. Excipients such as dextrin may be added if necessary. Purification can be carried out according to means known to those skilled in the art, such as synthetic adsorption resin, activated carbon, ion exchange resin, column chromatography, and recrystallization.

Pteropodine, Isopteropodyne, 6-Gingerol, and 6-Shogaol can also be produced by organically synthesizing, but are preferably derived from plants. These compounds are obtained by extracting from plants, and the extract is recovered by filtration, centrifugation, etc., and then purified by treatment such as concentration, adsorption, separation, elution, solvent removal, etc. It is preferable to have. Examples of plants used for extraction include cat's claw (Uncaria tomentosa) and ginger (Zingiber office). The synthesis method is not particularly limited, and a conventionally known method can be used.

The structure of the compound obtained by synthesis or purification can be identified according to means known to those of skill in the art. For example, proton nuclear magnetic resonance spectroscopy (1H-NMR), carbon nuclear magnetic resonance spectroscopy (13C-NMR), mass analysis (MS), elemental analysis, infrared spectroscopy (IR), ultraviolet spectroscopy (UV). ), The melting point measurement method, etc. may be used alone or in combination.

Since the above compound can also be obtained by extracting and purifying cat's claw (Uncaria tomentosa) and ginger (Zingiber office), the above cat's claw extract and ginger extract are preventive agents or treatments for new coronavirus infections. It is considered that it can also be used as an agent.

Further, in the above-mentioned compound, the "pharmaceutically acceptable salt" is typically a salt produced by the reaction of the above-mentioned compound with an acid or a base, and the "pharmaceutically acceptable ether" is typical. Refers to an ether produced by the reaction of the above compound with an alcohol, an alkoxide, or an organic halogen compound, which can maintain the effect of the above-mentioned compound for prevention or treatment of a new type coronavirus infection.

Cat's claw extract, ginger extract, Pteropodine and its pharmaceutically acceptable salt, Isopotapodin and its pharmaceutically acceptable salt e, 6-Gingerol and its pharmaceutically acceptable ether, and 6-Shogalol. And its pharmaceutically acceptable ethers have excellent prophylactic and therapeutic effects on new coronavirus infections. In particular, it is suitable for blending in the food composition, pharmaceutical composition, quasi-drug composition, cosmetic composition, and miscellaneous goods of the present invention described below.

The food composition is not particularly limited and may be appropriately selected depending on the intended purpose. For example, beverages such as soft beverages, carbonated beverages, nutritional beverages, fruit beverages, lactic acid beverages; candy, candy, chewables, jelly. , Gum, chocolate and other confectionery; various forms of health foods such as granules, tablets, capsules, drinks, functional foods and nutritional supplements.

The pharmaceutical composition is not particularly limited and can be appropriately selected according to the purpose, and examples thereof include tablets, capsules, drinks, and troches.

The quasi-drug composition is not particularly limited and may be appropriately selected according to the purpose. For example, disinfectants, masks, hand gels, medicated soaps, mouthwashes, bath salts, medicated toothpaste and the like can be used. Can be mentioned.

The cosmetic composition is not particularly limited and may be appropriately selected according to the purpose, and examples thereof include cosmetics, cosmetics, creams, milky lotions, hair styling products, hair washing products, and finishing cosmetics.

The miscellaneous goods are not particularly limited and may be appropriately selected according to the purpose. For example, disinfectant, mask, gloves, face shield, hand gel, spray, wet tissue, air purifier, aroma oil, etc. Examples include soap and toothpaste.

The food composition for the prevention or treatment of the new coronavirus infection, the pharmaceutical composition, the quasi-drug composition, the cosmetic composition, and the miscellaneous goods are suitably applied to humans, but each of them is used. It can also be applied to animals other than humans as long as the effect is obtained.

As described above, according to the present embodiment, food compositions, pharmaceutical compositions, and pharmaceuticals for the prevention or treatment of new coronavirus infections containing natural products or compounds derived from natural products, which are highly safe and easily available as raw materials, are contained. It is possible to provide quasi-drug compositions, cosmetic compositions, and miscellaneous goods.

Hereinafter, examples of the present invention will be described, but the present invention is not limited to these examples.

(Manufacturing Example 1)
-Isolation and purification of Pteropodine-
A cat's claw (Uncaria tomentosa) extract manufactured by Tokiwa Phytochemical Research Institute Co., Ltd. is heat-extracted under sulfuric acid acidic conditions. After adjusting the pH to neutral, an equal amount of methanol / chloroform mixed solution was added, liquid-liquid partitioning was performed, and then column purification using silica gel was performed. The fraction containing a large amount of Pteropodine was concentrated and dried, adsorbed again on a column packed with silica gel, eluted with a hexane / ethyl acetate mixed solution, and then recrystallized to obtain Pteropodine. The structure is shown in the chemical formula (1).

<1H-NMR (500MHz, CDCl3)>
δ1.40 (3H, d, J = 6.1Hz, 18-CH3), 1.51 (1H, m, 14β-H), 1.59 (1H, m, 20-H), 1.72 (1H) , Ddd, J = 12.1Hz, J = 4.3Hz, J = 4.3Hz, 14α-H), 1.99 (1H, m, 6α-H), 2.32 (1H, dd, J = 12) .1Hz, J = 3.8Hz, 21α-H) 2.36 (1H, dd, J = 12.1Hz, J = 4.3Hz, 3-H) 2.36 (1H, m, 5α-H) ), 2.40 (1H, ddd, J = 13.0Hz, J = 12.5Hz, 6β-H), 2.44 (1H, ddd, J = 12.1Hz, J = 4.7Hz, J = 4) .3Hz, 15-H), 3.30 (1H, ddd, J = 13.0Hz, J = 8.5Hz, J = 2.9Hz, 5β-H), 3.32 (1H, dd, J = 12) .1Hz, J = 2.0Hz, 21β-H) 3.60 (3H, s, 23-OCH3), 4.55 (1H, qd, J = 10.5Hz, J = 6.1Hz, 19-H ), 6.87 (1H, d, J = 7.6Hz, 12-H), 7.04 (1H, ddd, J = 7.6Hz, J = 7.3Hz, J = 1.0Hz, 10-H. ), 7.18 (1H, ddd, J = 7.6Hz, J = 7.6Hz, J = 1.2Hz, 11-H), 7.20 (1H, d, J = 7.3Hz, 9-H). ), 7.41 (1H, s, 17-H), 8.52 (1H, brs, NH)

(Manufacturing Example 2)
-Isolation and purification of Isopateropodine-
A cat's claw (Uncaria tomentosa) extract manufactured by Tokiwa Phytochemical Research Institute Co., Ltd. is heat-extracted under sulfuric acid acidic conditions. After adjusting the pH to neutral, an equal amount of methanol / chloroform mixed solution was added, liquid-liquid partitioning was performed, and then column purification using silica gel was performed. After concentrating and drying the hexane / ethyl acetate elution fraction, column purification using silica gel was performed again. After elution with a hexane / ethyl acetate mixed solution, it was recrystallized to obtain Isopteropodine. The structure is shown in the chemical formula (2).

<1H-NMR (500MHz, CDCl3)>
δ0.88 (1H, ddd, J = 11.7Hz, J = 11.7Hz, J = 11.7Hz, 14β-H), 1.41 (3H, d, J = 6.2Hz, 18-CH3), 1.59 (1H, m, 20-H), 1.62 (1H, ddd, J = 11.7Hz, J = 2.8Hz, J = 2.8Hz, 14α-H), 2.00 (1H, ddd, J = 11.9Hz, J = 7.6Hz, J = 7.6Hz, 6α-H) 2.39 (1H, ddd, J = 11.9Hz, J = 7.6Hz, J = 2.4Hz , 6β-H), 2.42 (1H, dd, J = 11.9Hz, J = 3.8Hz, 21-α), 2.46 (1H, ddd, J = 7.6Hz, J = 7.6Hz) , J = 7.6Hz, 5α-H), 2.51 (1H, ddd, J = 11.7Hz, J = 2.8Hz, J = 2.8Hz, 15-H), 2.57 (1H, dd) , J = 11.7Hz, J = 2.8Hz, 3-H), 3.22 (1H, ddd, J = 7.6Hz, J = 7.6Hz, J = 2.4Hz, 5β-H), 3 .29 (1H, dd, J = 11.9Hz, J = 1.8Hz, 21β-H) 3.60 (3H, s, 23-OCH3) 4.36 (1H, qd, J = 10.4Hz) , J = 6.2Hz, 19-H), 6.89 (1H, d, J = 7.7Hz, 12-H), 7.02 (1H, ddd, J = 7.7Hz, J = 7.7Hz) , J = 1.1Hz, 10-H), 7.19 (1H, ddd, J = 7.7Hz, J = 7.7Hz, J = 1.3Hz, 11-H), 7.27 (1H, d) , J = 7.7Hz, 9-H), 7.41 (1H, s, 17-H), 8.42 (1H, brs, NH)

(Manufacturing Example 3)
―6-Isolation and purification of Gingerol―
Methanol was added to the dried ginger (Zingiber officinale) pulverized product for extraction, and after concentration, water and diethyl ether were added to the concentrated solution for liquid-liquid partitioning. After concentrating the diethyl ether layer, column purification using silica gel was performed. After elution with hexane, a mixed solution of hexane / ethyl acetate, and methanol, the fraction containing a large amount of 6-Gingerol is concentrated, and further purified with 75% methanol using reverse phase high performance liquid chromatography (ODS), 6-. Obtained Gingerol. The structure is shown in the chemical formula (3).

<1H-NMR (500MHz, CDCl3)>
δ0.89 (3H, t, J = 7.0Hz, 10-CH3), 1.30 (6H, m, 7-2H, 8-2H, 9-2H), 1.38-1.49 (2H, m, 6-2H), 2.48 (1H, dd, J = 17.5Hz, J = 9.0Hz, 4-H), 2.57 (1H, dd, J = 17.5Hz, J = 2. 0Hz, 4-H), 2.73 (2H, m, 2-2H), 2.84 (2H, m, 1-2H), 3.87 (3H, s, 3'-OCH3), 4.02 (1H, m, 5-H), 6.66 (1H, dd, J = 8.0Hz, J = 2.0Hz, 6'-H), 6.68 (1H, d, J = 2.0Hz, 2'-H), 6.82 (1H, d, J = 8.0Hz, 5'-H)

(Manufacturing Example 4)
―6-Isolation and purification of Shogaol―
Methanol was added to the dried ginger (Zingiber officinale) pulverized product for extraction, and after concentration, water and diethyl ether were added to the concentrated solution for liquid-liquid partitioning. After concentrating the diethyl ether layer, column purification using silica gel was performed. After elution with hexane, a mixed solution of hexane / ethyl acetate, and methanol, the fraction containing a large amount of 6-shogaol is concentrated, and further purified with 35% acetonitrile using reverse phase high performance liquid chromatography (ODS), 6-. Shogaol was obtained. The structure is shown in the chemical formula (4).

<1H-NMR (600MHz, CDCl3)>
δ0.89 (3H, t, J = 8.7Hz, 10-CH3), 1.30 (4H, m, 8-2H, 9-2H), 1.45 (2H, m, 7-2H), 2 .19 (1H, ddd, J = 16.2Hz, J = 10.8Hz, J = 1.8Hz, 6-H) 2.85 (4H, m, 1-2H, 2-2H), 3.87 (3H, s, 3'-OCH3), 6.09 (1H, br d, J = 19.2Hz, 4-H), 6.68 (1H, dd, J = 9.6Hz, 2.4Hz, 6) '-H), 6.71 (1H, d, J = 2.4Hz, 2'-H), 6.80 (1H, m, 5-H), 6.83 (1H, d, J = 9. 6Hz, 5'-H)

(Example 1)
-Infection suppression effect of new coronavirus-
Using the compounds of Production Examples 1 to 4 as samples, the infection-suppressing effect of the new coronavirus was evaluated by the following test method.

The cells were added to VeroE6 / TMPRSS2 cell medium at a final concentration of 10 μM and cultured at 37 ° C. for 3 hours. Then, the new coronavirus SARS-CoV-2 (MOI = 0.05) was added to infect the cells. The cells were further cultured at 37 ° C. for 48 hours, CellTiter-Glo ^TM was added, and the cell viability was measured.
As the positive control, camostat and nafamostat, which are reported to be able to suppress the infection of the lung cells of the new coronavirus, were used.

From the results shown in FIG. 1, it was confirmed that the compounds of Production Examples 1 to 4 had a higher infection-suppressing effect on the new coronavirus than the positiveon camostat and nafamostat.

The IC50s of Production Examples 2 to 4 were calculated using the cell viability of VeroE6 / TMPRSS2 cells as an index.

(Example 2)
Virus infection was visualized by immunostaining with an antibody against SARS-CoV-2 Nprotein.
Production Example 2 and Production Example 3 were added to the medium of VeroE6 / TMPRSS2 cells at final concentrations of 10 μM, 25 μM, and 50 μM, cultured at 37 ° C. for 3 hours, and then the new coronavirus SARS-CoV-2 (MOI = 0.05) was added. It was added and infected the cells. Further, the cells were cultured at 37 ° C. for 24 hours, and the cells were fixed with 4% paraformaldehyde. Triton X-100 was added as a permeation treatment, and the treatment was carried out at room temperature for 15 minutes. After that, blocking treatment was performed at room temperature for 15 minutes with Blocking One ^TM . Immunostaining was carried out using SARS-CoV-2 Nucleocapsid Protein antibody (1: 100 dilution, Novus NB100-56576) for 1 hour at room temperature, followed by Alexa 568-labele anti-rabbit antibody (1: 100 dilution, Ther). Staining was performed at room temperature for 1 hour. Cell nuclei were stained with Prolong Gold Antifade Mount with DAPI (Thermo).

From the results shown in FIG. 2, when Production Examples 2 and 3 were added, a decrease in infected cells was observed in each of them in a concentration-dependent manner.

(Example 3)
We investigated whether the infection-suppressing effect on SARS-CoV-2 acts on cell invasion or after cell invasion.
Production Examples 2 and 3 having a final concentration of 50 μM were added to the medium of VeroE6 / TMPRSS2 cells under the following conditions. Under the conditions of Full time, the new coronavirus SARS-CoV-2 (MOI = 0.05) was added to the medium 3 hours before infection, and Production Examples 2 and 3 were present in the medium at 50 μM even after washing 2 hours after infection. I made it. Under the conditions of Entry, production examples 2 and 3 were added to the medium from 3 hours before infection with the new coronavirus SARS-CoV-2 (MOI = 0.05), and production examples 2 and 3 were present in the medium until after washing 2 hours after infection. Under the conditions of Post-entry, Production Examples 2 and 3 were allowed to exist from after washing 2 hours after infection with the new coronavirus SARS-CoV-2 (MOI = 0.05) to detection 48 hours after infection. For detection, CellTiter-Glo ^TM was added 48 hours after infection and cell viability was measured.

From the results shown in FIG. 3, it was confirmed that both Production Examples 2 and 3 act after cell invasion.

(Example 4)
Coronavirus synthesizes a peptide having a function by synthesizing a polyprotein, cleaving it at three sites with a papain-like enzyme, and then cleaving it at 11 sites with a 3CL protease.
Using a test system that can detect the cleavage reaction of polyprotein by protease by the Western Brod method, the inhibitory effect of protease on cleavage of polyprotein was investigated.
A peptide having an amino acid sequence cleaved by the new coronavirus SARS-CoV-23C L protease and 3CL protease (FLAG-TSITSAVLQ ^ SGFRKMAFP-GST-biotin) was synthesized using a wheat cell-free protein synthesis system. Add the synthesized protease and substrate, and Production Examples 2 and 3 at a final concentration of 500 μM, react at 37 ° C. for 3 hours, perform SDS-PAGE using 13% polyacrylamide gel, transfer to PVDF membrane, and blocking One. Blocking treatment was performed by ^TM at room temperature for 15 minutes. Then, detection was performed using anti-streptavidin-HRP antibody (1: 5000 dilution).

From the results shown in FIG. 4, both Production Examples 2 and 3 inhibited the cleavage of polyprotein by protease.

The present invention relates to cat's claw extract, ginger extract, Pteropodine and its quasi-drug salt, Isopteropodine and its quasi-drug salt, 6-Gingerol and its pharmaceutically acceptable ether, and the like. Industrial availability as a food composition, pharmaceutical composition, quasi-drug composition, cosmetic composition, miscellaneous goods containing at least one of 6-Gingerol and its pharmaceutically acceptable ether as an active ingredient. be.

Claims

A prophylactic or therapeutic agent for a new type of coronavirus infection containing a cat's claw (Uncaria tomentosa) extract.
A prophylactic or therapeutic agent for a new type of coronavirus infection containing a ginger (Zingiber office) extract.
A prophylactic or therapeutic agent for a new type of coronavirus infection containing at least one of Pteropodine and its pharmaceutically acceptable salt.
A prophylactic or therapeutic agent for a new type of coronavirus infection containing at least one of Isopteropodine and a pharmaceutically acceptable salt.
A prophylactic or therapeutic agent for a new type of coronavirus infection containing at least one of 6-Gingerol and a pharmaceutically acceptable ether.
A prophylactic or therapeutic agent for a new type of coronavirus infection containing at least one of 6-shogaol and a pharmaceutically acceptable ether.
A food composition, a pharmaceutical composition, a quasi-drug composition, a cosmetic composition, or a new coronavirus infection containing at least one of the extracts or compounds according to claims 1 to 6. ,general merchandise.